Work

DSP-0390, an oral emopamil binding protein (EBP) inhibitor, in patients with recurrent high-grade glioma: A first-in-human, phase 1 study.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.tps2077

Authors: David A. Reardon, Yoshitaka Narita, Yoshiki Arakawa, Samuel A. Goldlust, George Ansstas, Jian Mei, Edward Dow, Masataka Seki, Yudai Furuta, Gregory Song, Howard Colman

Institutions: Center for Neuro-Oncology, Dana-Farber Cancer Institute, National Cancer Center Hospital, Kyoto University, Hackensack University Medical Center, Washington University in St. Louis, Sumitomo Dainippon Pharma (Japan), University of Utah, Huntsman Cancer Institute

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Sumitomo Dainippon Pharma Oncology

OpenAlex ID: W4281784629

Cites:

Cited by: 2

Related to: 10